SCHEMBL2014361

SCHEMBL2014361

CC(=O)Oc1ccc(NCC(=O)OCc2ccccc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.56
ALDH1A1 P00352 7/20 0.54
MAPT P10636 3/20 0.54
HSP90AA1 P07900 1/20 0.54
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MAPK1 P28482 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
TSHR P16473 1/20 0.46
HTT P42858 1/20 0.46
HSD17B10 Q99714 1/20 0.46
ELANE P08246 1/20 0.45
POLB P06746 1/20 0.45
KMT2A Q03164 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21137668 0.87 ALDH1A1 (0.65) GAAALDH1A1MAPTRAB9ASMN1; SMN2
SCHEMBL11453114 0.86 ALDH1A1 (0.56) GAAALDH1A1MAPTNPC1RAB9A
SCHEMBL10832371 0.85 NPC1 (0.57) GAAALDH1A1MAPTNPC1RAB9A
SCHEMBL62534 0.84 ALDH1A1 (0.59) ALDH1A1MAPTMAPK1L3MBTL1POLB
SCHEMBL28257721 0.83 LMNA (0.53) GAAALDH1A1MAPTNPC1RAB9A
SCHEMBL11454434 0.83 ALDH1A1 (0.54) GAAALDH1A1MAPTHSP90AA1RAB9A
Hydrochloric Acid SCHEMBL27368126 0.82 ALDH1A1 (0.58) ALDH1A1MAPTMAPK1L3MBTL1POLB
SCHEMBL6901569 0.81 POLB (0.65) GAAALDH1A1MAPTHSP90AA1L3MBTL1
SCHEMBL1163051 0.81 GAA (0.66) GAAALDH1A1MAPTHSP90AA1NPC1
SCHEMBL6560866 0.81 HIF1A (0.56) GAAALDH1A1MAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964730-B2 Amino-substituted ethylamino β2 adrenergic receptor agonists THERAVANCE, INC. (US) 2011-06-21 US disclosed
US-20090111850-A1 Amino-Substituted Ethylamino Beta2 Adrenergic Receptor Agonists THERAVANCE BIOPHARMA R&D IP, LLC 2009-04-30 US disclosed
EP-1687257-B1 AMINO-SUBSTITUTED ETHYLAMINO BETA2 ADRENERGIC RECEPTOR AGONISTS THERAVANCE INC (US) 2009-04-15 EP disclosed
US-7399863-B2 Amino-substituted ethylamino β2 adrenergic receptor agonists THERAVANCE, INC. (US) 2008-07-15 US disclosed
US-20050113411-A1 Amino-substituted ethylamino beta2 adrenergic receptor agonists THERAVANCE BIOPHARMA R&D IP, LLC 2005-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111850-A1 Amino-Substituted Ethylamino Beta2 Adrenergic Receptor Agonists ADRB2, ADRB1, ADRA2A GAA 2480/4885ALDH1A1 989/4885MAPT 2527/4885
US-20050113411-A1 Amino-substituted ethylamino beta2 adrenergic receptor agonists ADRB2, ADRB1, ADRA2A GAA 2480/4885ALDH1A1 989/4885MAPT 2527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.